Source comparison
MOTS-c Side Effects in Studies: Safety Data Comparison
Kim et al., Clinical and Translational Medicine (2021) 5mg–50mg weekly subcutaneous 42 healthy adults Mild injection site erythema (7% of subjects) None 12 weeks Established baseline safety in healthy metabolic syndrome cohort. No dose-limiting toxicity observ
This comparison does not assign a generated winner or score.
- Kim et al., Clinical and Translational Medicine (2021)
- 5mg–50mg weekly subcutaneous
- 42 healthy adults
- Mild injection site erythema (7% of subjects)
- None
- 12 weeks
- Established baseline safety in healthy metabolic syndrome cohort. No dose-limiting toxicity observed across range
- Reynolds et al., Metabolism (2023)
- 15mg–30mg weekly subcutaneous
- 38 participants
- Transient headache within 24h of first dose (5% of subjects)
- 24 weeks
- Extended observation confirmed no cumulative toxicity or organ function changes. Safe for short-to-mid-term use
- Nakamura et al., Frontiers in Endocrinology (2024)
- 20mg weekly subcutaneous
- 18 participants
- Muscle cramping (1 subject, attributed to concurrent exercise)
- 26 weeks
- Longest published trial to date. Metabolic improvements sustained without safety signal emergence
- Zhang et al., Journal of Translational Medicine (2022)
- 10mg–40mg weekly subcutaneous
- 52 participants
- Mild nausea unrelated to injection timing (4% of subjects)
- 16 weeks
- Larger cohort replicated earlier findings. No laboratory abnormalities across comprehensive panels